Organization (Other)
Combined Military Hospital Abbottabad
ClinicalTrials.gov lists Combined Military Hospital Abbottabad as lead sponsor of 25 trials. It has 28 active development programs and 10 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section
18 sections measured, none recorded
This page covers Combined Military Hospital Abbottabad: 25 lead-sponsored trials and 0 legal-entity registrations.
Disease areas (17)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Hyperpigmentation | 5 |
| Melanosis | 5 |
| Mite Infestations | 2 |
| Molluscum Contagiosum | 2 |
| Papillomavirus Infections | 2 |
Showing 5 of 17 disease areas.
Trials by start year as sponsor or collaborator (3)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 4 |
| 2022 | 18 |
| 2021 | 4 |
No forecast is made for this organization: it averages 4.4 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 25 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
Active development programs (28)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Topical 1 % clotrimazole twice daily 2 weeks | Tinea Versicolor | Phase 1/2 | 1 |
| Oral itraconazole 200mg daily for 5 days | Tinea Versicolor | Phase 1/2 | 1 |
| Group A 4 % Hydroquinone Cream Topically and Oral Tranexamic Acid | Melanosis | Phase 1 | 1 |
| Group A 4 % Hydroquinone Cream Topically and Oral Tranexamic Acid | Hyperpigmentation | Phase 1 | 1 |
| Platelets Rich Plasma | Hyperpigmentation | Phase 1 | 1 |
Showing 5 of 28 active programs.
Approved assets (10)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Triple combination cream (fluocinolone acetonide + hydroquinone + tretinoin) alone | 1 |
| Itraconazole | 3 |
| Permethrin | 1 |
| Tranexamic Acid | 1 |
| Sulphur | 1 |
Showing 5 of 10 approved assets.
Journals published in (13)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Acta dermatovenerologica Alpina, Pannonica, et Adriatica | 1 |
| Anais brasileiros de dermatologia | 1 |
| Annals of parasitology | 1 |
| Contact dermatitis | 1 |
| Dermatology and therapy | 1 |
Showing 5 of 13 journals.
Latest dated events (26)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-09 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-07-15 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-05 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-02-02 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2022-11-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 26 events.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sponsor delivery record, us granted patents, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, organization relationships, clia clinical laboratory certificates, biomarker capability evidence, and biomarkers this organization publishes on.